相关实验视频
Updated: Jun 17, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
419
同时存在的Logopenic变体的初级渐进性失言症与粉样蛋白病理和早期帕金森症
Martina Caccamo1,2, Daniele Urso1,3, Alfredo Gabriele Nanni1,2
1Department of Clinical Research in Neurology, Center for Neurodegenerative Diseases and the Aging Brain, University of Bari 'Aldo Moro', "Pia Fondazione Cardinale G. Panico", Tricase, Lecce, Italy.
Journal of Alzheimer's disease reports
|August 8, 2024
概括
这项研究详细介绍了一个罕见的logoopenic初级渐进性失言症 (lvPPA) 病例,呈现出早期帕金森症. 它强调了语言缺陷,帕金森症症状和lvPPA中的粉样蛋白病理之间的复杂联系.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 语言学的语言学.
背景情况:
- 初级渐进性失言症 (PPA) 包含各种语言障碍.
- 帕金森症通常在PPA的后期阶段观察到,主要在非流利/语法亚型中.
- 语言变种 (lvPPA) 很少表现出帕金森特征.
研究的目的:
- 报告一个罕见的早期发病的帕金森症病例在逻辑性原发性渐进性失言症 (lvPPA).
- 调查语言障碍,帕金森症和lvPPA的潜在病理之间的关系.
主要方法:
- 一个63岁的男性患有语言困难和帕金森症的病例报告.
- 综合的神经检查,语言评估,神经成像和生物标志物分析.
主要成果:
- 患者出现了命名困难,发现词语的问题,刚性,布拉迪基尼西亚,静止震,厌氧症和便秘.
- 诊断证实为lvPPA与粉样蛋白病理和早期,突出的帕金森症.
- 语言评估显示,理解能力保持良好,但有句子重复问题和轻度的语音失语.
结论:
- 这一案例表明,帕金森症可以在lvPPA中早期和显著地表现出来.
- 突出了 lvPPA 中语言障碍,帕金森症和粉样蛋白病理之间的复杂关联.
- 建议在lvPPA的差异诊断中需要考虑帕金森症,即使在早期阶段也是如此.
相关概念视频
Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

